Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Riabni (rituximab-arrx)
i
Other names:
ABP 798 , ABP798, ABP-798
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
AbbVie, Amgen
Drug class:
CD20 inhibitor
Related drugs:
‹
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
F007 (rituximab biosimilar) (0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
(0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.